Long-term risk of venous thrombosis after stopping anticoagulants for a first unprovoked event: A multi-national cohort

Thrombosis Research

Volumn 143, Issue , 2016, Pages 152-158

  Rodger, Marc A ^a,b   Scarvelis, Dimitri ^a,b   Kahn, Susan R ^c,d   Wells, Philip S ^a,b   Anderson, David A ^e   Chagnon, Isabelle ^f   Le Gal, Grégoire ^a,b   Gandara, Esteban ^a,b   Solymoss, Susan ^c   Sabri, Elham ^a,b   Kovacs, Judy ^h   Kovacs, Michael J ^g  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e DALHOUSIE UNIVERSITY   (Canada)

^f HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^g UNIVERSITY OF WESTERN ONTARIO   (Canada)

^h LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

anticoagulants; prognosis; risk factors; therapy; Venous thrombosis

Indexed keywords

ANTICOAGULANT AGENT;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT DISEASE; RISK ASSESSMENT; VEIN THROMBOSIS; CANADA; CLINICAL TRIAL; MIDDLE AGED; PATHOLOGY; RISK FACTOR; VENOUS THROMBOSIS;

ANTICOAGULANTS; CANADA; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; RISK FACTORS; VENOUS THROMBOSIS;

EID: 84964318237     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2016.03.028     Document Type: Article

References (34)

1. [1] Baglin, T., Luddington, R., Brown, K., Baglin, C., Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilia risk factors: prospective cohort study. Lancet 362 (2003), 523–526.
2. [2] Kearon, C., Akl, E.A., Comerota, A.J., et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141 (2012), e419S–e494S.
3. [3] White, R.H., The epidemiology of venous thromboembolism. Circulation, 107, 2003 (I-4-I-8).
4. [4] Agnelli, G., Prandoni, P., Santamaria, M.G., et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N. Engl. J. Med. 345 (2001), 165–169.
5. [5] Prandoni, P., Lensing, A.W.A., Cogo, A., et al. The long-term clinical course of acute deep venous thrombosis. Ann. Intern. Med. 125 (1996), 1–7.
6. [6] Kearon, C., Gent, M., Hirsh, J., et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N. Engl. J. Med. 340 (1999), 901–907.
7. [7] Schulman, S., Rhedin, A.S., Lindmarker, P., et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N. Engl. J. Med. 332 (1995), 1661–1665.
8. [8] Research Committee of the British Thoracic Society, Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet 340 (1992), 873–876.
9. [9] Carrier, M., Le Gal, G., Wells, P.S., Rodger, M.A., Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann. Intern. Med. 152 (2010), 578–589.
10. [10] Castellucci, L.A., Cameron, C., Le Gal, G., et al. Safety and efficacy outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis. BMJ, 347, 2013, f5133.
11. [11] Castellucci, L.A., Cameron, C., Le, G.G., et al. Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis. BMJ, 347, 2013, f5133.
12. [12] Castellucci, L.A., Le, G.G., Rodger, M.A., Carrier, M., Major bleeding during secondary prevention of venous thromboembolism in patients who have completed anticoagulation: a systematic review and meta-analysis. J. Thromb. Haemost. 12 (2014), 344–348.
13. [13] Agnelli, G., Prandoni, P., Becattini, C., et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann. Intern. Med. 139 (2003), 19–25.
14. [14] Pinede, L., Ninet, J., Duhaut, P., et al. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation 103 (2001), 2453–2460.
15. [15] Couturaud, F., Sanchez, O., Pernod, G., et al. Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism: The PADIS-PE Randomized Clinical Trial. JAMA 314 (2015), 31–40.
16. [16] Prandoni, P., Noventa, F., Ghirarduzzi, A., et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 92 (2007), 199–205.
17. [17] Rodger, M.A., Kahn, S.R., Wells, P.S., et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ 179 (2008), 417–426.
18. [18] Kearon, C., LAFIT investigators. Abstract: Rate of recurrent venous thromboembolism (VTE) after completing two years of anticoagulation for a first episode of idiopathic VTE [abstract]. Thromb. Haemost., 2002, 86.
19. [19] Kahn, S.R., The post-thrombotic syndrome: the forgotten morbidity of deep venous thrombosis. J. Thromb. Thrombolysis 21 (2006), 41–48.
20. [20] Morange, P.E., Aillaud, M.-F., Nicaud, V., Henry, M., Juhan-Vague, I., Alal47Thr and C + 1542G polymorphisms in the TAFI gene are not associated with a higher risk of venous thrombosis in FV Leiden carriers. Thromb. Haemost. 86 (2001), 1583–1584.
21. [21] Prandoni, P., Lensing, A.W., Prins, M.H., et al. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann. Intern. Med. 137 (2002), 955–960.
22. [22] Piovella, F., Crippa, L., Barone, M., et al. Normalization rates of compression ultrasonography in patients with a first episode of deep vein thrombosis of the lower limbs: association with recurrence and new thrombosis. Haematologica 87 (2002), 515–522.
23. [23] Brochier, M., Raynaud, P., Fauchier, J.P., et al. Comparison between lung scans and pulmonary angiograms in the evaluation of the perfusion defect in massive and submassive pulmonary embolism. Prog. Resp. Res. 13 (1980), 120–126.
24. [24] Wells, P.S., Anderson, D.R., Rodger, M., et al. Evaluation of D-Dimer in the diagnosis of suspected deep-vein thrombosis. N. Engl. J. Med. 349 (2003), 1227–1235.
25. [25] McRae, S., Tran, H., Schulman, S., Ginsberg, J., Kearon, C., Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis. Lancet 368 (2006), 371–378.
26. [26] Verhovsek, M., Douketis, J.D., Yi, Q., et al. Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann. Intern. Med. 149 (2008), 481–490 (W-94).
27. [27] Carrier, M., Rodger, M.A., Wells, P.S., Righini, M., Le, G.G., Residual vein obstruction to predict the risk of recurrent venous thromboembolism in patients with deep vein thrombosis: a systematic review and meta-analysis. J. Thromb. Haemost. 9 (2011), 1119–1125.
28. [28] Donadini, M.P., Ageno, W., Antonucci, E., et al. Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis. A patient-level meta-analysis. Thromb. Haemost. 111 (2014), 172–179.
29. [29] Eichinger, S., Heinze, G., Jandeck, L.M., Kyrle, P.A., Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation 121 (2010), 1630–1636.
30. [30] Tosetto, A., Iorio, A., Marcucci, M., et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J. Thromb. Haemost. 10 (2012), 1019–1025.
31. [31] Schulman, S., Lindmarker, P., Holmstrom, M., et al. Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J. Thromb. Haemost. 4 (2006), 734–742.
32. [32] Stain, M., Schonauer, V., Minar, E., et al. The post-thrombotic syndrome: risk factors and impact on the course of thrombotic disease. J. Thromb. Haemost. 3 (2005), 2671–2676.
33. [33] Hamadah, A., Alwasaidi, T., Le, G.G., et al. Baseline imaging after therapy for unprovoked venous thromboembolism: a randomized controlled comparison of baseline imaging for diagnosis of suspected recurrence. J. Thromb. Haemost. 9 (2011), 2406–2410.
34. [34] McGinn, T.G., Guyatt, G.H., Wyer, P.C., et al. Users' guides to the medical literature: XXII: how to use articles about clinical decision rules. Evidence-Based Medicine Working Group. JAMA 284 (2000), 79–84.